

# Two tick-borne diseases in one: a case report of concurrent babesiosis and Lyme disease in Ontario



Claudia C. dos Santos, MD; Kevin C. Kain, MD

## Case

A 59-year-old man presented to The Toronto Hospital on July 27, 1997, because of fever. His travel history included a trip to Nantucket, Mass., 6 weeks before presentation and to Southeast Asia 7 months earlier. There was no history of rural travel on either trip. The past medical history was noncontributory. The patient had not undergone splenectomy, nor had he ever received a blood transfusion.

The patient had been well until June 21, 1997, when he noticed a small "pinhead" lesion on his left biceps, which he removed. He subsequently experienced fever and spreading erythema (to 5 cm in diameter) surrounding the site of the lesion; the erythema subsequently resolved. He was then well until July 21, when the fever returned, along with rigors, extreme fatigue, headache, myalgia, vomiting and drenching night sweats. On July 22 he saw his family physician, who diagnosed a viral infection. On presentation to the hospital 5 days later, the patient was febrile (temperature 38.8°C) and pale and appeared unwell. He had tachycardia (130 beats/minute), splenomegaly and scattered petechiae. Laboratory investigations revealed anemia, marked thrombocytopenia and a bleeding diathesis (Table 1).

His fever and travel to Southeast Asia suggested malaria; smears were ordered, and the results were initially interpreted as positive for *Plasmodium falciparum* (4% parasitemia). However, a senior technologist reviewed the smears a few hours later and correctly identified the organisms as trophozoites of *Babesia*.

Given the severity of his illness and the preceding rash consistent with erythema migrans, there were concerns about coinfection with additional tick-borne agents. Serologic testing for Lyme disease was performed, and the results of both enzyme-linked immunosorbent assay and Western blotting for IgM were positive, which indicated recent infection. Serologic testing for human monocytic ehrlichiosis (*Ehrlichia chaffeensis*) by immunofluorescence assay, performed at the Ontario Provincial Laboratory, was negative at 1:64 dilution. Polymerase chain reaction assays for human granulocytic and monocytic ehrlichiosis were performed in the laboratory of one of the authors (K.C.K.); the results were negative.<sup>1</sup>

The patient was treated with quinine (600 mg three times daily) and clindamycin (600 mg three times daily) for 7 days for the babesiosis and doxycycline (100 mg twice a day) for 21 days for the Lyme disease. The response was prompt, and smear testing yielded negative results by day 4. When seen at follow-up the patient was asymptomatic, and all laboratory measurements had returned to normal.

## Comments

Babesiosis (caused by *Babesia microti*) and Lyme disease (caused by *Borrelia burgdorferi*) are emerging diseases in the northeastern United States. Their frequency is increasing as the deer tick (*Ixodes scapularis*), which transmits both organisms, increases in distribution.<sup>2,3</sup> Because *B. microti* and *B. burgdorferi* have the same rodent reservoir and are transmitted by the same vector, human coinfection may be more common than appreciated. In support of this hypothesis, up to 66% of residents of Long Island, NY, who have Lyme disease also have antibodies to *Babesia* sp.<sup>4</sup> Although coinfections have been infrequently described, recent reports indicate that the severity and duration of illness are greater in coinfecting patients.<sup>5-8</sup>

*I. scapularis* ticks have been found in several Canadian provinces, and 205 cases of Lyme disease were reported in this country between 1984 and 1994.<sup>9,10</sup> However, no case of babesiosis has ever been reported in Canada, and there have been no

Education

Éducation

From the Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine, The Toronto Hospital and University of Toronto, Toronto, Ont.

This article has been peer reviewed.

CMAJ 1999;160:1851-3



previous reports of coinfection. We have described a Canadian with a severe illness caused by concurrent babesiosis and Lyme disease.<sup>11</sup>

*Babesia* spp. are intracellular parasites that may be confused with malaria-causing organisms both clinically and morphologically.<sup>12-14</sup> The features of *Babesia* that permit its discrimination from *Plasmodium falciparum* include the presence of paired piriform stages and a tetrad configuration (the "Maltese cross") formed by binary fission of the trophozoite.

The nymph stages of *I. scapularis* are small (less than 3 mm) and are primarily responsible for transmission of both babesiosis and Lyme disease.<sup>15</sup> It is possible that the lesion removed by our patient was a nymphal-stage tick. Nymphs typically feed in May and June, which results in a peak of clinical illness in July. As in this case, the symptoms of babesiosis usually begin 1 to 4 weeks later.<sup>15</sup> The clinical spectrum ranges from mild to life-threatening infection, the latter characterized by severe hemolytic anemia, thrombocytopenia and renal failure.<sup>15</sup> Mortality rates are higher in elderly people, those who have undergone splenectomy and those with HIV infection.<sup>15,16</sup>

Coinfection with other tick-borne agents is an important determinant of outcome. The illness associated with concurrent babesiosis and Lyme disease is more severe than either infection alone.<sup>5-8</sup> Krause and colleagues<sup>8</sup> reported that 11% of patients with Lyme disease were coinfecting with *B. microti*.<sup>8</sup> Overall, patients with coinfections reported a greater number, severity and duration of symptoms. Coinfected patients had significantly more fatigue, headache, sweats, chills, nausea, conjunctivitis and splenomegaly than those with Lyme disease alone. Furthermore, 50% of these patients were ill for 3 months or more, whereas only 7% of those with Lyme disease alone were ill for that period.

The mechanism by which human babesiosis and Lyme disease each potentiate the severity of the other remains unknown. Animal experiments indicate that *Babesia* infections may impair host defence mechanisms.<sup>8,17</sup> These immunosuppressive effects may explain why it is possible to

detect DNA from *Borrelia* spirochetes in people with coinfections more frequently and for longer periods than in patients with Lyme disease alone.<sup>18</sup> *Babesia* infections enhance the manifestations of Lyme disease in mice, which suggests that coinfection might also potentiate the pathogenicity of *B. burgdorferi* infections in humans.<sup>17</sup> Finally, a synergistic inflammatory reaction has also been suggested as a putative cause for the increased severity of disease in patients with coinfections.<sup>8</sup>

Recently, evidence of coinfection with a third tick-transmitted zoonotic parasite, *Ehrlichia*, has been reported.<sup>14,19,20</sup> These studies indicate that tick-borne diseases are widespread and prevalent in some regions of the United States. Canadians will be at risk when they visit these areas during tick season (generally from May to September). *I. scapularis* and *I. pacificus* ticks have been identified in about 250 locations in Canada, although established populations are focal and are at present limited to Ontario and British Columbia.<sup>9,10</sup> Prolonged parasitemia accompanying coinfection involving babesiosis may facilitate transmission of the organism to ticks in areas of Canada where established *Ixodes* populations exist, such as Long Point peninsula in Point Pelee National Park.<sup>8-10</sup> Finally, blood products are not screened for *Babesia* spp. or *B. burgdorferi*, both of which can be transmitted by blood transfusion.<sup>21,22</sup>

In summary, given the current levels of travel between Canada and the US and the emergence of Lyme disease, babesiosis and ehrlichiosis, we must anticipate an increase in the number of imported cases of these pathogens in Canadians. Patients with a tick-transmitted infection should be assessed for coinfection with other known agents, particularly if the symptoms are severe or persist after therapy.

## References

1. Sumner JW, Nicholson WL, Massung RF. PCR amplification and comparison of nucleotide sequences from the groESL heat shock operon of *Ehrlichia* species. *J Clin Microbiol* 1997;35:2087-92.
2. White DJ, Chang HG, Benach JL, Bosler EM, Meldrum SC, Means RG, et al. The geographic spread and temporal increase of the Lyme disease epidemic. *JAMA* 1991;266:1230-6.
3. Daniels TJ, Falco RC, Schwartz I, Varde S, Robbins RG. Deer ticks (*Ixodes scapularis*) and the agents of Lyme disease and human granulocytic ehrlichiosis in a New York city park. *Emerging Infect Dis* 1997;3:353-5.
4. Benach JL, Coleman JL, Habicht GS, MacDonald A, Grunwaldt E, Giron JA. Serologic evidence for simultaneous occurrences of Lyme disease and babesiosis. *J Infect Dis* 1985;152:473-8.
5. Grunwaldt E, Barbour AG, Benach JL. Simultaneous occurrence of babesiosis and Lyme disease [letter]. *New Engl J Med* 1983;308:1166.
6. Marcus LC, Steere AC, Duray PH, Anderson AE, Mahoney EB. Fatal pericarditis in a patient with coexistent Lyme disease and babesiosis: demonstration of spirochetes in the myocardium. *Ann Intern Med* 1985;103:374-6.
7. Golightly LM, Hirschorn LR, Weller PF. Fever and headache in a splenectomized woman. *Rev Infect Dis* 1989;11:629-37.
8. Krause PJ, Telford SR 3rd, Spielman A, Sikand V, Ryan R, Christianson D. Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illness. *JAMA* 1996;275:1657-60.
9. Lindsay R, Artsob H, Barker I. Distribution of *Ixodes pacificus* and *Ixodes scapularis* re concurrent babesiosis and Lyme disease. *Can Commun Dis Rep* 1998;24:121-2.
10. Banerjee SN, Christensen CI, Scott JD. Isolation of *Borrelia burgdorferi* on mainland Ontario. *Can Commun Dis Rep* 1995;21:85-6.
11. dos Santos C, Kain K. Concurrent babesiosis and Lyme disease diagnosed in Ontario. *Can Commun Dis Rep* 1998;24(12):97-101.
12. Loutan L, Rossier J, Zufferey G, Cuenod D, Hatz C, Martin HP, et al. Imported babesiosis diagnosed as malaria. *Lancet* 1993;342:749.
13. Quick RE, Herwaldt BL, Thomford JW, Garnett ME, Eberhard ML, Wilson

**Table 1: Laboratory measurements for a 59-year-old man with fever and drenching night sweats**

Test	Result	Normal range
Hemoglobin, g/dL	10.6	13.5-17.5
Leukocytes, x 10 <sup>9</sup> /L	4.2	4.5-11.0
Platelets, x 10 <sup>9</sup> /L	14	150-400
Lactate dehydrogenase, U/L	799	45-90
Bilirubin, µmol/L	26	2-17
Aspartate aminotransferase, U/L	151	8-20
Haptoglobin, g/dL	< 0.012	0.06-0.29
D-dimers, ng/mL	< 250	500-1000
Fibrinogen, µmol/L*	12.4	4.4-10.3
FDP, µg/mL	> 10	< 2.5
International normalized ratio	4.89	1

Note: FDP = fibrinogen degradation product.

\*The SI unit for fibrinogen is micromoles per litre, where 1 g/dL = 29.41 µmol/L.



- M, et al. Babesiosis in Washington state: a new species of *Babesia*? *Ann Intern Med* 1993;119:284-90.
14. Fritz CL, Kjemtrup AM, Conrad PA, Flores GR, Campbell GL, Schriefer ME, et al. Seroepidemiology of emerging tickborne infectious disease in a northern California community. *J Infect Dis* 1997;175:1432-9.
  15. Spach DH, Liles WC, Campbell GL, Quick RE, Anderson DE Jr, Fritsche TR. Tick-borne diseases in the United States. *New Engl J Med* 1993;329:936-47.
  16. Benezra D, Brown AE, Polsky B, Gold JWM, Armstrong D. Babesiosis and infection with human immunodeficiency virus [letter]. *Ann Intern Med* 1987;107:944.
  17. Kimsey PB, Kimsey RB, Telford SR 3rd. Cardiac sequelae of Lyme disease: simulation in the BALB/c mouse [abstract]. *Clin Res* 1990;38:596.
  18. Armstrong AL, Barthold SW, Persing DH, Beck DS. Carditis in Lyme disease susceptible and resistant strains of laboratory mice infected with *Borrelia burgdorferi*. *Am J Trop Med Hyg* 1992;47:249-58.
  19. Mitchell PD, Reed KD, Hofkes JM. Immunoserologic evidence of coinfection with *Borrelia burgdorferi*, *Babesia microti*, and human granulocytic *Ehrlichia* species in residents of Wisconsin and Minnesota. *J Clin Microbiol* 1996;34:724-7.
  20. Magnarelli LA, Dumler S, Anderson JF, Johnson RC, Fikrig E. Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera. *J Clin Microbiol* 1995;33:3054-7.
  21. Mintz ED, Anderson JF, Cable RG, Hadler JL. Transfusion-transmitted babesiosis: a case from an endemic area. *Transfusion* 1991;31:365-8.
  22. Herwaldt BL, Kjemtrup AM, Conrad PA, Barnes RC, Wilson M, McCarthy MG. Transfusion-transmitted babesiosis in Washington state: first reported case caused by a WA-1 type parasite. *J Infect Dis* 1997;175:1259-62.

**Reprint requests to:** Dr. Kevin C. Kain, Director, Tropical Disease Unit, EN G-224, The Toronto Hospital, 200 Elizabeth St., Toronto ON M5G 2C4; fax 416 595-5826



ASSOCIATION  
MÉDICALE  
CANADIENNE

CANADIAN  
MEDICAL  
ASSOCIATION

## Canadian Medical Association 132nd Annual Meeting

22-25 August 1999



**Westin Ottawa**  
**Host: Ontario Medical Association**  
**Registration and travel information:**  
**CMA Meetings and Travel**  
**800 663-7336 or 613 731-8610 ext. 2383**  
**Fax: 613 731-8047**



Association médicale canadienne

## 132<sup>e</sup> Assemblée annuelle

du 22 au 25 août 1999

**Westin d'Ottawa**  
**Votre hôte : l'Association médicale de l'Ontario**  
**Pour inscription et information de voyage :**  
**Conférences et voyages de l'AMC**  
**800 663-7336 ou 613 731-8610 poste 2383**  
**Fax : 613 731-8047**